Avian Influenza in Humans: Clinical Presentation and One Health Surveillance

Introduction

Avian influenza viruses (AIVs) of the genus Influenzavirus A (family Orthomyxoviridae) constitute a significant zoonotic threat originating from domestic and wild avian reservoirs. Although these viruses are primarily adapted to avian hosts, sporadic spillover events into human populations have been documented, particularly involving the highly pathogenic avian influenza (HPAI) subtype H5N1 and the low pathogenic avian influenza (LPAI) subtype H7N9 [1, 2]. The clinical spectrum in humans ranges from mild upper respiratory tract infection to severe viral pneumonia with multi-organ failure, and case fatality rates vary markedly between subtypes. This article provides a comprehensive review of the clinical presentation of avian influenza in humans from a veterinary One Health perspective, emphasizing the critical role of surveillance in avian populations, diagnostic methodologies, and the integrated frameworks necessary for pandemic preparedness.

Given that avian influenza remains an enzootic pathogen in poultry and wild birds, surveillance in these populations is the cornerstone of early warning systems. The veterinary practitioner and diagnostician must understand the virological, epidemiological, and clinical features of human infections to effectively contribute to interdisciplinary surveillance networks. This article draws direct parallels between avian pathology and human disease expression, focusing on host-range barriers, viral receptor binding, and the biophysical mechanisms underlying cross-species transmission.

Virological Subtypes and Host Range Determinants

Influenza A viruses are classified by hemagglutinin (HA) and neuraminidase (NA) surface glycoproteins. To date, 16 HA and 9 NA subtypes circulate in aquatic birds, with H5 and H7 subtypes possessing the capacity to evolve into highly pathogenic forms following introduction into domestic poultry. Among these, H5N1 and H7N9 have caused the majority of documented human infections [3].

The host range restriction is largely governed by the binding specificity of HA for sialic acid (SA) receptors. Avian influenza viruses preferentially bind alpha-2,3-linked SA receptors, which are abundant in the respiratory tract of birds and in the human lower respiratory tract (bronchioles and alveoli). Human influenza viruses preferentially bind alpha-2,6-linked SA receptors, predominant in the human upper respiratory tract. The H5N1 virus retains a strong alpha-2,3 specificity, necessitating deep lung exposure for infection, which contributes to its high pathogenicity but relatively inefficient human-to-human transmission. H7N9 viruses, in contrast, have acquired mutations that enhance binding to both alpha-2,3 and alpha-2,6 receptors, facilitating upper respiratory tract infection and increasing pandemic potential [2, 4].

Table 1 summarizes the key virological and epidemiological characteristics of the major zoonotic AIV subtypes.

Table 1: Comparison of Major Zoonotic Avian Influenza Subtypes

Data compiled from World Organisation for Animal Health and World Health Organization reports [1, 5].

Transmission from Birds to Humans

Direct or indirect contact with infected poultry or contaminated environments represents the primary route of human infection. Live bird markets, backyard flocks, and uncontrolled poultry movement are well-documented risk factors. The virus is shed in high concentrations in avian feces and respiratory secretions. Human infection occurs via inhalation of aerosolized virus, direct mucosal inoculation, or fomite contact. Consumption of properly cooked poultry products does not pose a risk, as the virus is inactivated at temperatures above 70 degrees Celsius [2].

Sustained human-to-human transmission has not been documented for H5N1 or H7N9, although clusters of infections among family members have raised concern for limited, non-sustained transmission. The absence of efficient airborne transmission among humans is attributed to the receptor binding profile and the lack of adaptive mutations in the polymerase complex (e.g., PB2 E627K) that enhance replication in mammalian cells [3].

Clinical Presentation in Humans

The incubation period for avian influenza in humans ranges from 2 to 8 days, longer than that of seasonal influenza. Clinical illness is characterized by the rapid onset of fever (temperature exceeding 38 degrees Celsius), cough, dyspnea, and myalgia. Upper respiratory symptoms such as rhinorrhea and sore throat are less prominent than in seasonal influenza, particularly for H5N1 infections [2].

Gastrointestinal symptoms (diarrhea, vomiting, abdominal pain) are reported in a substantial proportion of H5N1 patients, reflecting the virus's ability to infect intestinal epithelium via alpha-2,3 receptors present in the gut. In H7N9 infections, conjunctivitis is a frequent presenting sign, attributed to the virus's affinity for ocular mucosal receptors [4].

Disease progression is often rapid. Within 24 to 48 hours of symptom onset, patients develop severe viral pneumonia, acute respiratory distress syndrome (ARDS), and multi-organ failure. Lymphopenia, thrombocytopenia, and elevated liver enzymes are common laboratory findings. Secondary bacterial pneumonia (e.g., due to Streptococcus pneumoniae or Staphylococcus aureus) can complicate the clinical course [5].

The case fatality rate (CFR) for H5N1 is approximately 53%, while for H7N9 it is approximately 39%. The higher CFR for H5N1 is linked to its propensity to cause a cytokine storm (hypercytokinemia) with massive pulmonary inflammation. H7N9, although somewhat less lethal, affects an older demographic and often presents with underlying comorbidities, which influences mortality [1, 4].

Diagnostic Testing

Laboratory confirmation of avian influenza in humans relies on molecular detection of viral RNA, viral isolation, or serological assays. The following modalities are employed in reference and surveillance laboratories.

Molecular Diagnostics

Real-time reverse transcriptase polymerase chain reaction (rRT-PCR) targeting the matrix (M) gene is the first-line diagnostic assay. Subtype-specific assays targeting HA genes for H5, H7, and H9 are used for confirmation. Nasopharyngeal swabs, throat swabs, and lower respiratory tract specimens (bronchoalveolar lavage, endotracheal aspirate) yield the highest viral loads. Viral RNA detection in the lower respiratory tract is often positive even when upper respiratory specimens are negative, especially in H5N1 infections [6].

Sequencing of the HA cleavage site and the neuraminidase gene provides information on pathogenicity and antiviral resistance. High-throughput sequencing platforms enable genomic surveillance and phylogenetic analysis, critical for detecting reassortment events.

Serological Assays

Serological diagnosis requires paired acute and convalescent sera (14 to 21 days apart). The hemagglutination inhibition (HI) assay is the standard serological test, although it is less sensitive for detecting antibodies against H5 and H7 subtypes. Microneutralization assays are more specific and are considered the gold standard for avian influenza serology. Enzyme-linked immunosorbent assays (ELISAs) using recombinant HA proteins are also employed for screening.

For further information on ELISA principles, refer to the article on Enzyme-Linked Immunosorbent Assay (ELISA) for Feline Leukemia Virus, which discusses the general mechanism of antigen capture assays.

Viral Isolation

Inoculation of clinical specimens into embryonated chicken eggs (specific pathogen free) or MDCK cell lines is performed in biosafety level 3 (BSL-3) facilities. Viral isolation is essential for antigenic characterization and antiviral susceptibility testing.

Table 2 summarizes the diagnostic methods and their applications in human and avian surveillance.

Table 2: Diagnostic Assays for Avian Influenza

Abbreviation: BAL, bronchoalveolar lavage.

Treatment

Antiviral therapy with neuraminidase inhibitors (oseltamivir, zanamivir) is the mainstay of treatment. Early administration within 48 hours of symptom onset is associated with improved survival, although many patients present late. Oseltamivir resistance has been documented, particularly in H5N1 strains with the H274Y mutation in the neuraminidase gene. Intravenous peramivir and the polymerase inhibitor baloxavir marboxil are alternative agents [5].

Supportive care includes mechanical ventilation for ARDS, extracorporeal membrane oxygenation (ECMO) in refractory cases, and management of multi-organ dysfunction. Corticosteroids are generally not recommended due to potential suppression of antiviral immune responses and increased risk of secondary infections.

Pandemic Preparedness and One Health Surveillance

A One Health approach integrates surveillance across human, animal, and environmental domains to detect and respond to emerging zoonotic threats. For avian influenza, surveillance in wild bird populations, domestic poultry, and live bird markets provides early warning of virus introduction and evolution.

Sentinel Surveillance in Poultry

Veterinary services conduct routine virological surveillance in poultry flocks, targeting clinically ill birds and dead birds. Hemagglutination assays and rRT-PCR are used for typing. The presence of HPAI H5 or H7 triggers immediate notification to the World Organisation for Animal Health (WOAH).

Human Surveillance

Human surveillance involves case finding among individuals with severe acute respiratory infection (SARI) and a history of poultry exposure. Laboratory confirmation and genomic characterization are linked to animal surveillance data through shared databases.

Integrated Data Sharing Platforms

Platforms such as the Global Influenza Surveillance and Response System (GISRS) enable real-time sharing of virological and epidemiological data across sectors. Veterinary and public health laboratories must coordinate sample sharing and data standardization.

The following Mermaid diagram illustrates the integrated One Health surveillance workflow for avian influenza.

flowchart TD
    A[Wild bird populations], >|Fecal sampling| B[Veterinary reference laboratory]
    C[Poultry flocks], >|Clinical surveillance| B
    D[Live bird markets], >|Swab sampling| B
    B, >|rRT-PCR, sequencing| E{Subtype identification}
    E, >|HPAI H5/H7 detected| F[WOAH notification]
    E, >|LPAI with zoonotic markers| F
    F, > G[Enhanced surveillance in humans]
    G, > H[Human SARI surveillance]
    H, >|Respiratory specimens| I[Public health laboratory]
    I, >|rRT-PCR, sequencing| J[Comparison with avian strains]
    J, >|Genetic similarity| K[Risk assessment]
    K, > L[Pandemic preparedness actions]
    L, > M[Poultry culling, movement restrictions]
    L, > N[Antiviral stockpile deployment]
    L, > O[Vaccine strain selection]

Vaccine Development

Vaccine preparedness includes the development of candidate vaccine viruses (CVVs) for H5N1 and H7N9 that are antigenically matched to circulating strains. These CVVs are generated using reverse genetics to attenuate the HA cleavage site. Some CVVs have been pre-approved by regulatory agencies for rapid large-scale production.

Biosecurity in Poultry Production

Strict biosecurity measures in poultry farms and live bird markets reduce the risk of virus amplification and spillover. Measures include segregation of species, regular cleaning and disinfection, and prohibition of overnight holding of unsold birds. For further context, see the article on Avian Influenza (HPAI) Spread: Transmission Pathways, Biosecurity, and Clinical Implications.

Differential diagnosis of respiratory and systemic diseases in poultry is critical. Clinicians should differentiate avian influenza from other etiologies such as Infectious Coryza in Poultry and Ducks and Fowl Cholera (Fowl Cholera in Poultry).

Conclusion

Avian influenza in humans remains a rare but severe zoonotic disease with high pandemic potential. The clinical presentation is dominated by lower respiratory tract involvement, rapid progression to ARDS, and high case fatality rates, particularly for H5N1. Prevention relies on rigorous surveillance in avian populations, rapid diagnostic testing using molecular methods, and integrated One Health collaboration. Veterinary practitioners are essential sentinels in this system, as early detection of HPAI or LPAI strains with zoonotic markers in poultry can trigger interventions that prevent human cases. Continued investment in cross-sectoral surveillance, antiviral stockpiling, and vaccine development is essential for pandemic preparedness.

References

[1] World Health Organization. Avian influenza A (H5N1) and A (H7N9) infections in humans: global case counts and clinical management guidelines. Geneva: WHO; 2023.

[2] World Organisation for Animal Health. Avian influenza: technical disease cards. Paris: WOAH; 2023.

[3] Centers for Disease Control and Prevention. Avian influenza A viruses: information for clinicians. Atlanta: CDC; 2023.

[4] Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med. 2013;368(20):1888-1897.

[5] Beigel JH, Farrar J, Han AM, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med. 2005;353(13):1374-1385.

[6] World Health Organization. WHO guidelines for the collection of human specimens for laboratory diagnosis of avian influenza. Geneva: WHO; 2013.